bluuebunny/crossref_metadata_2025 huggingface dataset:
Table S1 from Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer
Authors: Yun Mi Ran , Kim Dong Hwi , Kim Seok-Young , Joo Hyeong-Seok , Lee You Won , Choi Hun Mi , Park Chae Won , Heo Seong Gu , Kang Han Na , Lee Sung Sook , Schoenfeld Adam J. , Drilon Alexander , Kang Seok-Gu , Shim Hyo Sup , Hong Min Hee , Cui J. Jean , Kim Hye Ryun , Cho Byoung Chul
Published: April 2023

Supplementary table 1
Supplementary Data from Arginine Starvation and Docetaxel Induce c-Myc–Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors
Authors: Prudner Bethany C. , Rathore Richa , Robinson Anthony M. , Godec Abigail , Chang Samuel F. , Hawkins William G. , Hirbe Angela C. , Van Tine Brian A.
Published: April 2023

supplementary figures and tables
Supplementary Data from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
Authors: Wainberg Zev A. , Hochster Howard S. , Kim Edward J. , George Ben , Kaylan Aparna , Chiorean E. Gabriela , Waterhouse David M. , Guiterrez Martin , Parikh Aparna , Jain Rishi , Carrizosa Daniel Ricardo , Soliman Hatem H. , Lila Thomas , Reiss David J. , Pierce Daniel W. , Bhore Rafia , Banerjee Sibabrata , Lyons Larry , Louis Chrystal U. , Ong Teng Jin , O'Dwyer Peter J.
Published: April 2023

Methods
Figure S5. Tumor Epithelial/Stromal Compartment CD8+ T-Cell Ratio in Tissue-Matched Metastatic Tumors (arm B parts 1 and 2) from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
Authors: Wainberg Zev A. , Hochster Howard S. , Kim Edward J. , George Ben , Kaylan Aparna , Chiorean E. Gabriela , Waterhouse David M. , Guiterrez Martin , Parikh Aparna , Jain Rishi , Carrizosa Daniel Ricardo , Soliman Hatem H. , Lila Thomas , Reiss David J. , Pierce Daniel W. , Bhore Rafia , Banerjee Sibabrata , Lyons Larry , Louis Chrystal U. , Ong Teng Jin , O'Dwyer Peter J.
Published: April 2023

Baseline (screening) vs treatment cycle 2 (P=.06; paired t test). For patient 5, baseline data were not available.
Supplementary Figure 3 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer
Authors: Wang Yifan , Park Jin Yong Patrick , Pacis Alain , Denroche Robert E. , Jang Gun Ho , Zhang Amy , Cuggia Adeline , Domecq Celine , Monlong Jean , Raitses-Gurevich Maria , Grant Robert C. , Borgida Ayelet , Holter Spring , Stossel Chani , Bu Simeng , Masoomian Mehdi , Lungu Ilinca M. , Bartlett John M.S. , Wilson Julie M. , Gao Zu-Hua , Riazalhosseini Yasser , Asselah Jamil , Bouganim Nathaniel , Cabrera Tatiana , Boucher Louis-Martin , Valenti David , Biagi James , Greenwood Celia M.T. , Polak Paz , Foulkes William D. , Golan Talia , O'Kane Grainne M. , Fischer Sandra E. , Knox Jennifer J. , Gallinger Steven , Zogopoulos George
Published: April 2023

Supplementary Figure 3 shows the histological analysis of the xenografts evaluated in the preclinical trial
Supplementary Figure S4 from Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells
Authors: Ichikawa Junya , Yoshida Tatsuya , Isser Ariel , Laino Andressa S. , Vassallo Melinda , Woods David , Kim Sojung , Oelke Mathias , Jones Kristi , Schneck Jonathan P. , Weber Jeffrey S.
Published: April 2023

Functional analysis of MART-1 Tet+ CD8+ T-cells against melanoma cell lines.
Supplementary Data from Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas
Authors: Wildes Tyler J. , Dyson Kyle A. , Francis Connor , Wummer Brandon , Yang Changlin , Yegorov Oleg , Shin David , Grippin Adam , Dean Bayli DiVita , Abraham Rebecca , Pham Christina , Moore Ginger , Kuizon Carmelle , Mitchell Duane A. , Flores Catherine T.
Published: April 2023

Supplementary Data
Supplementary Table 2 from Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia
Authors: Laurent Anouchka P. , Siret Aurélie , Ignacimouttou Cathy , Panchal Kunjal , Diop M'Boyba , Jenni Silvia , Tsai Yi-Chien , Roos-Weil Damien , Aid Zakia , Prade Nais , Lagarde Stephanie , Plassard Damien , Pierron Gaelle , Daudigeos Estelle , Lecluse Yann , Droin Nathalie , Bornhauser Beat C. , Cheung Laurence C. , Crispino John D. , Gaudry Muriel , Bernard Olivier A. , Macintyre Elizabeth , Barin Bonnigal Carole , Kotecha Rishi S. , Geoerger Birgit , Ballerini Paola , Bourquin Jean-Pierre , Delabesse Eric , Mercher Thomas , Malinge Sebastien
Published: April 2023

List of the SNVs identified through whole exome sequencing
Supplementary Data: R analysis code from Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab
Authors: Hopkins Ashley M. , Kichenadasse Ganessan , Garrett-Mayer Elizabeth , Karapetis Christos S. , Rowland Andrew , Sorich Michael J.
Published: April 2023

R analysis code for model development
Figure S6. from Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
Authors: Merz Valeria , Zecchetto Camilla , Santoro Raffaela , Simionato Francesca , Sabbadini Fabio , Mangiameli Domenico , Piro Geny , Cavaliere Alessandro , Deiana Michela , Valenti Maria Teresa , Bazan Diana , Fedele Vita , Lonardi Sara , Melisi Davide
Published: April 2023

The differences in mean progression-free survival duration of patients in the discovery cohort are estimated for each value of eotaxin (A), GM-CSF (B), Gro alpha(C), IL-12p70 (D), IL-13 (E), IL-18 (F), IL-1 beta (G), IL-2 (H), IL-4 (I), IL-5 (J), IL-6 (K), IFN gamma (L), IP-10 (M), MCP-1 (N), MIP-1 alpha (O), MIP-1 beta (P), RANTES (Q), SDF-1alpha (R) and TNF-alpha (S).
Figure S5. from Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
Authors: Merz Valeria , Zecchetto Camilla , Santoro Raffaela , Simionato Francesca , Sabbadini Fabio , Mangiameli Domenico , Piro Geny , Cavaliere Alessandro , Deiana Michela , Valenti Maria Teresa , Bazan Diana , Fedele Vita , Lonardi Sara , Melisi Davide
Published: April 2023

HRs for progression-free survival duration of patients in the discovery cohort for different values for each cytokine evaluated: eotaxin (A), GM-CSF (B), Gro-alpha (C), IL-12p70 (D), IL-13 (E), IL-18 (F), IL-1 beta (G), IL-2 (H), IL-4 (I), IL-5 (J), IL-6 (K), IFN gamma (L), IP-10 (M), MCP-1 (N), MIP-1alpha (O), MIP-1 beta(P), RANTES (Q), SDF-1alpha (R) and TNF-alpha (S).
Supplementary Fig. S3 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
Authors: Carrato Cristina , Alameda Francesc , Esteve-Codina Anna , Pineda Estela , Arpí Oriol , Martinez-García Maria , Mallo Mar , Gut Marta , Lopez-Martos Raquel , Barco Sonia Del , Ribalta Teresa , Capellades Jaume , Puig Josep , Gallego Oscar , Mesia Carlos , Muñoz-Marmol Ana M , Archilla Ivan , Arumí Montserrat , Blanc Julie Marie , Bellosillo Beatriz , Menendez Silvia , Esteve Anna , Bagué Silvia , Hernandez Ainhoa , Craven-Bartle Jordi , Fuentes Rafael , Vidal Noemí , Aldecoa Iban , Iglesia Nuria de la , Balana Carmen
Published: April 2023

IHC protein expression of IDH1, EGFR (intensity 3 as high versus 0-2), high intensity, PTEN, OLIG2, Ki67 and SOX2 by IGS (first row) and TCGA subtype (second row: KNN, third row: SVM, fourth row: ssGSEA). Significant differences were seen between mesenchymal and classical or proneural tumors. See Supplementary Data File S1e for results simplified in Table 1.
Supplementary Fig S1 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
Authors: Carrato Cristina , Alameda Francesc , Esteve-Codina Anna , Pineda Estela , Arpí Oriol , Martinez-García Maria , Mallo Mar , Gut Marta , Lopez-Martos Raquel , Barco Sonia Del , Ribalta Teresa , Capellades Jaume , Puig Josep , Gallego Oscar , Mesia Carlos , Muñoz-Marmol Ana M , Archilla Ivan , Arumí Montserrat , Blanc Julie Marie , Bellosillo Beatriz , Menendez Silvia , Esteve Anna , Bagué Silvia , Hernandez Ainhoa , Craven-Bartle Jordi , Fuentes Rafael , Vidal Noemí , Aldecoa Iban , Iglesia Nuria de la , Balana Carmen
Published: April 2023

In 38 sequenced samples classified according to the Support Vector Machine (SVM) algorithm, heatmaps were plotted to compare the expression of the top 50 genes between (A) classical and mesenchymal, (B) mesenchymal and proneural, and (C) classical and proneural subtypes.
Supplementary Data Legends from Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma
Authors: Meel Michaël H. , de Gooijer Mark C. , Metselaar Dennis S. , Sewing A. Charlotte P. , Zwaan Kenn , Waranecki Piotr , Breur Marjolein , Buil Levi C.M. , Lagerweij Tonny , Wedekind Laurine E. , Twisk Jos W.R. , Koster Jan , Hashizume Rintaro , Raabe Eric H. , Montero Carcaboso Ángel , Bugiani Marianna , Phoenix Timothy N. , van Tellingen Olaf , van Vuurden Dannis G. , Kaspers Gertjan J.L. , Hulleman Esther
Published: April 2023

Legends pertaining to supplementary figures and tables
Supplementary Table S1 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Authors: Autio Karen A. , Klebanoff Christopher A. , Schaer David , Kauh John Sae Wook , Slovin Susan F. , Adamow Matthew , Blinder Victoria S. , Brahmachary Manisha , Carlsen Michelle , Comen Elizabeth , Danila Daniel C. , Doman Thompson N. , Durack Jeremy C. , Fox Josef J. , Gluskin Jill S. , Hoffman David M. , Kang Suhyun , Kang Praneet , Landa Jonathan , McAndrew Philomena F. , Modi Shanu , Morris Michael J. , Novosiadly Ruslan , Rathkopf Dana E. , Sanford Rachel , Chapman Sonya C. , Tate Courtney M. , Yu Danni , Wong Phillip , McArthur Heather L.
Published: April 2023

Best overall response by RECIST 1.1 and PCWG2 for bone.
Supplementary Figure S3 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Authors: Autio Karen A. , Klebanoff Christopher A. , Schaer David , Kauh John Sae Wook , Slovin Susan F. , Adamow Matthew , Blinder Victoria S. , Brahmachary Manisha , Carlsen Michelle , Comen Elizabeth , Danila Daniel C. , Doman Thompson N. , Durack Jeremy C. , Fox Josef J. , Gluskin Jill S. , Hoffman David M. , Kang Suhyun , Kang Praneet , Landa Jonathan , McAndrew Philomena F. , Modi Shanu , Morris Michael J. , Novosiadly Ruslan , Rathkopf Dana E. , Sanford Rachel , Chapman Sonya C. , Tate Courtney M. , Yu Danni , Wong Phillip , McArthur Heather L.
Published: April 2023

Assessment of tumor associated macrophage depletion using macrophage gene signature. The downward trend (pre vs post, indicating depletion of TAMs) of the gene signature did not appear pronounced in any of the patient samples except for patient C.
Supplementary Figure S1 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Authors: Autio Karen A. , Klebanoff Christopher A. , Schaer David , Kauh John Sae Wook , Slovin Susan F. , Adamow Matthew , Blinder Victoria S. , Brahmachary Manisha , Carlsen Michelle , Comen Elizabeth , Danila Daniel C. , Doman Thompson N. , Durack Jeremy C. , Fox Josef J. , Gluskin Jill S. , Hoffman David M. , Kang Suhyun , Kang Praneet , Landa Jonathan , McAndrew Philomena F. , Modi Shanu , Morris Michael J. , Novosiadly Ruslan , Rathkopf Dana E. , Sanford Rachel , Chapman Sonya C. , Tate Courtney M. , Yu Danni , Wong Phillip , McArthur Heather L.
Published: April 2023

Change in tumor biomarkers by response (RECIST) during LY3022855 treatment.
Supplementary Data from Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma
Authors: Bassaganyas Laia , Pinyol Roser , Esteban-Fabró Roger , Torrens Laura , Torrecilla Sara , Willoughby Catherine E. , Franch-Expósito Sebastià , Vila-Casadesús Maria , Salaverria Itziar , Montal Robert , Mazzaferro Vincenzo , Camps Jordi , Sia Daniela , Llovet Josep M.
Published: April 2023

Supplementary Materials and Methods, Supplementary Figures and Supplementary Tables
Figure S3 from Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non–Small Cell Lung Cancer
Authors: Liu Bin , Ricarte Filho Julio , Mallisetty Apurva , Villani Cassandra , Kottorou Anastasia , Rodgers Kristen , Chen Chen , Ito Tomoaki , Holmes Kyla , Gastala Nicole , Valyi-Nagy Klara , David Odile , Gaba Ron C. , Ascoli Christian , Pasquinelli Mary , Feldman Lawrence E. , Massad Malek G. , Wang Tza-Huei , Jusue-Torres Ignacio , Benedetti Enrico , Winn Robert A. , Brock Malcolm V. , Herman James G. , Hulbert Alicia
Published: April 2023

Figure S3
Supplemental Figure 4 from CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes
Authors: Leuci Valeria , Donini Chiara , Grignani Giovanni , Rotolo Ramona , Mesiano Giulia , Fiorino Erika , Gammaitoni Loretta , D'Ambrosio Lorenzo , Merlini Alessandra , Landoni Elisa , Medico Enzo , Capellero Sonia , Giraudo Lidia , Cattaneo Giulia , Iaia Ilenia , Pignochino Ymera , Basiricò Marco , Vigna Elisa , Pisacane Alberto , Fagioli Franca , Ferrone Soldano , Aglietta Massimo , Dotti Gianpietro , Sangiolo Dario
Published: April 2023

Th1 and Th2 cytokine production by CSPG4-CAR.CIK and CSPG4-CAR.T
Supplementary Figure Legends from A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer
Authors: Prat Aleix , Tsai Yi-Hsuan , Pascual Tomás , Paré Laia , Adamo Barbara , Vidal Maria , Brasó-Maristany Fara , Galván Patricia , Brase Jan Christoph , Rodrik-Outmezguine Vanessa , Johnston Stephen , Ciruelos Eva , Parker Joel S.
Published: April 2023

Supplementary Figure Legends
Suppl. Video 1 from CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes
Authors: Leuci Valeria , Donini Chiara , Grignani Giovanni , Rotolo Ramona , Mesiano Giulia , Fiorino Erika , Gammaitoni Loretta , D'Ambrosio Lorenzo , Merlini Alessandra , Landoni Elisa , Medico Enzo , Capellero Sonia , Giraudo Lidia , Cattaneo Giulia , Iaia Ilenia , Pignochino Ymera , Basiricò Marco , Vigna Elisa , Pisacane Alberto , Fagioli Franca , Ferrone Soldano , Aglietta Massimo , Dotti Gianpietro , Sangiolo Dario
Published: April 2023

CSPG4-CAR.CIK vs S5 - CYTOTOXICITY
Supplementary Tables from Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial
Authors: Mei Qian , Zhang Wenying , Liu Yang , Yang Qingming , Rasko John E.J. , Nie Jing , Liu Jiejie , Li Xiang , Dong Liang , Chen Meixia , Zhang Yan , Shi Lu , Wu Huitao , Han Weidong
Published: April 2023

This file contains 5 supplementary tables.
Appendix from AsiDNA Is a Radiosensitizer with no Added Toxicity in Medulloblastoma Pediatric Models
Authors: Ferreira Sofia , Foray Chloe , Gatto Alberto , Larcher Magalie , Heinrich Sophie , Lupu Mihaela , Mispelter Joel , Boussin François D. , Pouponnot Célio , Dutreix Marie
Published: April 2023

Appendix
Table S2 from Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis
Authors: Indraccolo Stefano , De Salvo Gian Luca , Verza Martina , Caccese Mario , Esposito Giovanni , Piga Ilaria , Del Bianco Paola , Pizzi Marco , Gardiman Marina Paola , Eoli Marica , Rudà Roberta , Brandes Alba Ariela , Ibrahim Toni , Rizzato Simona , Lolli Ivan , Zagonel Vittorina , Lombardi Giuseppe
Published: April 2023

MVD values in GBM samples
Supplemental Figure 3 from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer
Authors: Dunphy Mark P.S. , Pressl Christina , Pillarsetty Nagavarakishore , Grkovski Milan , Modi Shanu , Jhaveri Komal , Norton Larry , Beattie Bradley J. , Zanzonico Pat B. , Zatorska Danuta , Taldone Tony , Ochiana Stefan O. , Uddin Mohammad M. , Burnazi Eva M. , Lyashchenko Serge K. , Hudis Clifford A. , Bromberg Jacqueline , Schöder Heiko M. , Fox Josef J. , Zhang Hanwen , Chiosis Gabriela , Lewis Jason S. , Larson Steven M.
Published: April 2023

Tumor PU-H71 retention at 24 hours post-injection (quantified by standard uptake value) is not explained by plasma radiotracer exposure (quantified by plasma AUC from 10 min to 4 h post-injection, see Methods), as indicated by Spearman Test R-value.
Supplemental Figure 2 from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer
Authors: Dunphy Mark P.S. , Pressl Christina , Pillarsetty Nagavarakishore , Grkovski Milan , Modi Shanu , Jhaveri Komal , Norton Larry , Beattie Bradley J. , Zanzonico Pat B. , Zatorska Danuta , Taldone Tony , Ochiana Stefan O. , Uddin Mohammad M. , Burnazi Eva M. , Lyashchenko Serge K. , Hudis Clifford A. , Bromberg Jacqueline , Schöder Heiko M. , Fox Josef J. , Zhang Hanwen , Chiosis Gabriela , Lewis Jason S. , Larson Steven M.
Published: April 2023

Supplemental Figure 2. Tumor PU-H71 retention at 24 hours post-injection (quantified by standard uptake value) is not explained by plasma radiotracer exposure (quantified by plasma AUC from 10 min to 4 h post-injection, see Methods), as indicated by Spearman Test R-value.
Supplementary Table S7 from Noninvasive Detection of Urothelial Carcinoma by Cost-effective Low-coverage Whole-genome Sequencing from Urine-Exfoliated Cell DNA
Authors: Zeng Shuxiong , Ying Yidie , Xing Naidong , Wang Baiyun , Qian Ziliang , Zhou Zunlin , Zhang Zhensheng , Xu Weidong , Wang Huiqing , Dai Lihe , Gao Li , Zhou Tie , Ji Jiatao , Xu Chuanliang
Published: April 2023

Comparison between the results of UroCAD and urine cytology tests in the training group.
Supplementary Figure S1 from Noninvasive Detection of Urothelial Carcinoma by Cost-effective Low-coverage Whole-genome Sequencing from Urine-Exfoliated Cell DNA
Authors: Zeng Shuxiong , Ying Yidie , Xing Naidong , Wang Baiyun , Qian Ziliang , Zhou Zunlin , Zhang Zhensheng , Xu Weidong , Wang Huiqing , Dai Lihe , Gao Li , Zhou Tie , Ji Jiatao , Xu Chuanliang
Published: April 2023

UroCAD reproduce testing results among different sampling time points
Table S4 from Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study
Authors: Bagley Stephen J. , Nabavizadeh S. Ali , Mays Jazmine J. , Till Jacob E. , Ware Jeffrey B. , Levy Scott , Sarchiapone Whitney , Hussain Jasmin , Prior Timothy , Guiry Samantha , Christensen Theresa , Yee Stephanie S. , Nasrallah MacLean P. , Morrissette Jennifer J.D. , Binder Zev A. , O'Rourke Donald M. , Cucchiara Andrew J. , Brem Steven , Desai Arati S. , Carpenter Erica L.
Published: April 2023

Complete list of variants detected in 20 subjects who had both tissue and plasma next generation sequencing
Supplementary Data from A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients
Authors: Zeh Herbert J. , Bahary Nathan , Boone Brian A. , Singhi Aatur D. , Miller-Ocuin Jennifer Lee , Normolle Daniel P. , Zureikat Amer H. , Hogg Melissa E. , Bartlett David L. , Lee Kenneth K. , Tsung Allan , Marsh J. Wallis , Murthy Pranav , Tang Daolin , Seiser Natalie , Amaravadi Ravi K. , Espina Virginia , Liotta Lance , Lotze Michael T.
Published: April 2023

Supplementary Data
Supplementary Figure 6 from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
Authors: Ladomersky Erik , Zhai Lijie , Lauing Kristen L. , Bell April , Xu Jiahui , Kocherginsky Masha , Zhang Bin , Wu Jennifer D. , Podojil Joseph R. , Platanias Leonidas C. , Mochizuki Aaron Y. , Prins Robert M. , Kumthekar Priya , Raizer Jeffrey J. , Dixit Karan , Lukas Rimas V. , Horbinski Craig , Wei Min , Zhou Changyou , Pawelec Graham , Campisi Judith , Grohmann Ursula , Prendergast George C. , Munn David H. , Wainwright Derek A.
Published: April 2023

Supplemental Figure 6. Characterization of the potent clinical-grade IDO enzyme inhibitor, BGB-7204.
Supplementary Figure 2 from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
Authors: Ladomersky Erik , Zhai Lijie , Lauing Kristen L. , Bell April , Xu Jiahui , Kocherginsky Masha , Zhang Bin , Wu Jennifer D. , Podojil Joseph R. , Platanias Leonidas C. , Mochizuki Aaron Y. , Prins Robert M. , Kumthekar Priya , Raizer Jeffrey J. , Dixit Karan , Lukas Rimas V. , Horbinski Craig , Wei Min , Zhou Changyou , Pawelec Graham , Campisi Judith , Grohmann Ursula , Prendergast George C. , Munn David H. , Wainwright Derek A.
Published: April 2023

Supplemental Figure 2. Glioblastoma patient overall survival.
Supplementary Data from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
Authors: Ladomersky Erik , Zhai Lijie , Lauing Kristen L. , Bell April , Xu Jiahui , Kocherginsky Masha , Zhang Bin , Wu Jennifer D. , Podojil Joseph R. , Platanias Leonidas C. , Mochizuki Aaron Y. , Prins Robert M. , Kumthekar Priya , Raizer Jeffrey J. , Dixit Karan , Lukas Rimas V. , Horbinski Craig , Wei Min , Zhou Changyou , Pawelec Graham , Campisi Judith , Grohmann Ursula , Prendergast George C. , Munn David H. , Wainwright Derek A.
Published: April 2023

Supplementary Materials and Methods
Table S2 from The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval
Authors: Jordan Kimberly R. , Sikora Matthew J. , Slansky Jill E. , Minic Angela , Richer Jennifer K. , Moroney Marisa R. , Hu Junxiao , Wolsky Rebecca J. , Watson Zachary L. , Yamamoto Tomomi M. , Costello James C. , Clauset Aaron , Behbakht Kian , Kumar T. Rajendra , Bitler Benjamin G.
Published: April 2023

Normalization factors for each dataset calculated based on housekeeping genes and sample size and power analysis.
Figure S5 from Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy
Authors: Zhou Katherine I. , Peterson Bryan , Serritella Anthony , Thomas Joseph , Reizine Natalie , Moya Stephanie , Tan Carol , Wang Yan , Catenacci Daniel V.T.
Published: April 2023

Supplementary Figure S5. Overall survival stratified by PD-L1 expression.
Figure S4 from Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy
Authors: Zhou Katherine I. , Peterson Bryan , Serritella Anthony , Thomas Joseph , Reizine Natalie , Moya Stephanie , Tan Carol , Wang Yan , Catenacci Daniel V.T.
Published: April 2023

Supplementary Figure S4. Comparison of TMB before vs. after chemotherapy.
Supplementary Materials and Data from Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations
Authors: Zhang Daniel Y. , Dmello Crismita , Chen Li , Arrieta Victor A. , Gonzalez-Buendia Edgar , Kane J. Robert , Magnusson Lisa P. , Baran Aneta , James C. David , Horbinski Craig , Carpentier Alexandre , Desseaux Carole , Canney Michael , Muzzio Miguel , Stupp Roger , Sonabend Adam M.
Published: April 2023

Supplementary Methods and Materials Figures S1: Schematic representation of LIPU generator set up. Supp Table 1: Summary of histological evaluation of CNS after one course of US-PTX Supp. Table 2: STR results of PDX cell lines. Figures S2: Cell viability in response to PTX and ABX
Supplementary Data from Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry
Authors: Verheijden Rik J. , May Anne M. , Blank Christian U. , Aarts Maureen J.B. , van den Berkmortel Franchette W.P.J. , van den Eertwegh Alfonsus J.M. , de Groot Jan Willem B. , Boers-Sonderen Marye J. , van der Hoeven Jacobus J.M. , Hospers Geke A. , Piersma Djura , van Rijn Rozemarijn S. , ten Tije Albert J. , van der Veldt Astrid A.M. , Vreugdenhil Gerard , van Zeijl Michiel C.T. , Wouters Michel W.J.M. , Haanen John B.A.G. , Kapiteijn Ellen , Suijkerbuijk Karijn P.M.
Published: April 2023

Suppl. tab. S1 | Multivariable Cox regression of baseline factors associated with overall survival in all first-line checkpoint inhibitor treated patients Suppl. tab. S2 | Multivariable Cox regression of baseline factors associated with overall survival in first-line checkpoint inhibitor treated patients experiencing severe immune related adverse events managed with immunosuppression
Supplementary fig 15 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Authors: Axelrod Margaret L. , Nixon Mellissa J. , Gonzalez-Ericsson Paula I. , Bergman Riley E. , Pilkinton Mark A. , McDonnell Wyatt J. , Sanchez Violeta , Opalenik Susan R. , Loi Sherene , Zhou Jing , Mackay Sean , Rexer Brent N. , Abramson Vandana G. , Jansen Valerie M. , Mallal Simon , Donaldson Joshua , Tolaney Sara M. , Krop Ian E. , Garrido-Castro Ana C. , Marotti Jonathan D. , Shee Kevin , Miller Todd W. , Sanders Melinda E. , Mayer Ingrid A. , Salgado Roberto , Balko Justin M.
Published: April 2023

Supplementary Figure 15: Differential analysis to identify candidate genes for blood-based detection.
Supplementary fig 10 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Authors: Axelrod Margaret L. , Nixon Mellissa J. , Gonzalez-Ericsson Paula I. , Bergman Riley E. , Pilkinton Mark A. , McDonnell Wyatt J. , Sanchez Violeta , Opalenik Susan R. , Loi Sherene , Zhou Jing , Mackay Sean , Rexer Brent N. , Abramson Vandana G. , Jansen Valerie M. , Mallal Simon , Donaldson Joshua , Tolaney Sara M. , Krop Ian E. , Garrido-Castro Ana C. , Marotti Jonathan D. , Shee Kevin , Miller Todd W. , Sanders Melinda E. , Mayer Ingrid A. , Salgado Roberto , Balko Justin M.
Published: April 2023

Supplementary Figure 10: Example FACS gating to identify PD-1HI CD8+ T cells from peripheral blood.
Figure S2 from Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition
Authors: Basler Lucas , Gabryś Hubert S. , Hogan Sabrina A. , Pavic Matea , Bogowicz Marta , Vuong Diem , Tanadini-Lang Stephanie , Förster Robert , Kudura Ken , Huellner Martin W. , Dummer Reinhard , Guckenberger Matthias , Levesque Mitchell P.
Published: April 2023

Partial dependence plots of the multivariate models for PP-prediction.
Supplementary Data from Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)
Authors: Johnson Douglas B. , Zhao Fengmin , Noel Marcus , Riely Gregory J. , Mitchell Edith P. , Wright John J. , Chen Helen X. , Gray Robert J. , Li Shuli , McShane Lisa M. , Rubinstein Larry V. , Patton David , Williams P. Mickey , Hamilton Stanly R. , Conley Barbara A. , Arteaga Carlos L. , Harris Lyndsay N. , O'Dwyer Peter J. , Chen Alice P. , Flaherty Keith T.
Published: April 2023

Supplementary Figure 6: (A) PFS and (B) OS of patients based on presence of concurrent mutation in PI3K-AKT pathway.
Supplementary Data from Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)
Authors: Johnson Douglas B. , Zhao Fengmin , Noel Marcus , Riely Gregory J. , Mitchell Edith P. , Wright John J. , Chen Helen X. , Gray Robert J. , Li Shuli , McShane Lisa M. , Rubinstein Larry V. , Patton David , Williams P. Mickey , Hamilton Stanly R. , Conley Barbara A. , Arteaga Carlos L. , Harris Lyndsay N. , O'Dwyer Peter J. , Chen Alice P. , Flaherty Keith T.
Published: April 2023

Supplementary Figure 9: (A) PFS and (B) OS of patients based on BRAF mutation class (class 2 vs. class 3).
Table S3 from An Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma
Authors: Chen Yue , Li Zhi-Yong , Zhou Guan-Qun , Sun Ying
Published: April 2023

Correlation between IRGPI subgroups and clinicopathological factors in the TCGA cohort
Table S1 from An Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma
Authors: Chen Yue , Li Zhi-Yong , Zhou Guan-Qun , Sun Ying
Published: April 2023

KEGG pathways and GO terms enriched in immune-related genes
Supplementary Table S2 from Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy
Authors: Noordhoek Iris , Treuner Kai , Putter Hein , Zhang Yi , Wong Jenna , Meershoek-Klein Kranenbarg Elma , Duijm-de Carpentier Marjolijn , van de Velde Cornelis J.H. , Schnabel Catherine A. , Liefers Gerrit-Jan
Published: April 2023

Summary of predictive performance of BCI (H/I) in the overall cohort and Primary AI subset based on primary endpoint, RFI and secondary endpoints DFI and DFS.
Suppl Figure Legend from Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair
Authors: Higuchi Fumi , Nagashima Hiroaki , Ning Jianfang , Koerner Mara V.A. , Wakimoto Hiroaki , Cahill Daniel P.
Published: April 2023

Supplementary Figure Legend
Suppl Figure 2 from Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair
Authors: Higuchi Fumi , Nagashima Hiroaki , Ning Jianfang , Koerner Mara V.A. , Wakimoto Hiroaki , Cahill Daniel P.
Published: April 2023

XRCC1 inactivation does not restore the sensitivity to TMZ in MSH6-deficient cells
Table S1 from Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
Authors: Gandhi Shipra , Pandey Manu R. , Attwood Kristopher , Ji Wenyan , Witkiewicz Agnieszka K. , Knudsen Erik S. , Allen Cheryl , Tario Joseph D. , Wallace Paul K. , Cedeno Carlos D. , Levis Maria , Stack Suzanne , Funchain Pauline , Drabick Joseph J. , Bucsek Mark J. , Puzanov Igor , Mohammadpour Hemn , Repasky Elizabeth A. , Ernstoff Marc S.
Published: April 2023

Adverse events by grade and frequency regardless of attribution
Supplementary Data Tables from Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis
Authors: Yin Lingdi , Pu Ning , Thompson Elizabeth , Miao Yi , Wolfgang Christopher , Yu Jun
Published: April 2023

Supplementary Data Tables
Supplementary Fig. S3 from Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study
Authors: Zhang Li , Meng Li , Liu Bingcheng , Zhang Yanli , Zhu Huanling , Cui Jiuwei , Sun Aining , Hu Yu , Jin Jie , Jiang Hao , Zhang Xi , Li Yan , Liu Li , Zhang Wanggang , Liu Xiaoli , Gu Jian , Qiao Jianhui , Ouyang Guifang , Liu Xin , Luo Jianmin , Jiang Ming , Xie Xiaobao , Li Jianyong , Zhao Chunting , Zhang Mei , Yang Tonghua , Wang Jianxiang
Published: April 2023

Time to MMR (A) and CCyR (B) MMR, and (C) Kaplan-Meier estimate of probability of progression to AP/BC or death due to CML while on treatment.
Figure S2 from Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection
Authors: Jolissaint Joshua S. , Soares Kevin C. , Seier Kenneth P. , Kundra Ritika , Gönen Mithat , Shin Paul J. , Boerner Thomas , Sigel Carlie , Madupuri Ramyasree , Vakiani Efsevia , Cercek Andrea , Harding James J. , Kemeny Nancy E. , Connell Louise C. , Balachandran Vinod P. , D'Angelica Michael I. , Drebin Jeffrey A. , Kingham T. Peter , Wei Alice C. , Jarnagin William R.
Published: April 2023

Figure S2
Figure S13 from Deep Learning for Fully Automated Prediction of Overall Survival in Patients with Oropharyngeal Cancer Using FDG-PET Imaging
Authors: Cheng Nai-Ming , Yao Jiawen , Cai Jinzheng , Ye Xianghua , Zhao Shilin , Zhao Kui , Zhou Wenlan , Nogues Isabella , Huo Yuankai , Liao Chun-Ta , Wang Hung-Ming , Lin Chien-Yu , Lee Li-Yu , Xiao Jing , Lu Le , Zhang Ling , Yen Tzu-Chen
Published: April 2023

Treatment analyses, DeepPET-OPSCC risk category, HPV- and TNM IVB, entire cohort with known HPV
Figure S11 from Deep Learning for Fully Automated Prediction of Overall Survival in Patients with Oropharyngeal Cancer Using FDG-PET Imaging
Authors: Cheng Nai-Ming , Yao Jiawen , Cai Jinzheng , Ye Xianghua , Zhao Shilin , Zhao Kui , Zhou Wenlan , Nogues Isabella , Huo Yuankai , Liao Chun-Ta , Wang Hung-Ming , Lin Chien-Yu , Lee Li-Yu , Xiao Jing , Lu Le , Zhang Ling , Yen Tzu-Chen
Published: April 2023

KM analyses, DeepPET-OPSCC risk category with four groups, discovery cohort
Figure S10 from Deep Learning for Fully Automated Prediction of Overall Survival in Patients with Oropharyngeal Cancer Using FDG-PET Imaging
Authors: Cheng Nai-Ming , Yao Jiawen , Cai Jinzheng , Ye Xianghua , Zhao Shilin , Zhao Kui , Zhou Wenlan , Nogues Isabella , Huo Yuankai , Liao Chun-Ta , Wang Hung-Ming , Lin Chien-Yu , Lee Li-Yu , Xiao Jing , Lu Le , Zhang Ling , Yen Tzu-Chen
Published: April 2023

KM analyses, DeepPET-OPSCC risk category with three groups, discovery cohort
Figure S2 from A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer
Authors: Shafique Michael R. , Fisher Terrence L. , Evans Elizabeth E. , Leonard John E. , Pastore Desa Rae E. , Mallow Crystal L. , Smith Ernest , Mishra Vikas , Schröder Andreas , Chin Kevin M. , Beck Joseph T. , Baumgart Megan A. , Govindan Ramaswamy , Gabrail Nashat Y. , Spira Alexander I. , Seetharamu Nagashree , Lou Yanyan , Mansfield Aaron S. , Sanborn Rachel E. , Goldman Jonathan W. , Zauderer Maurice
Published: April 2023

PK/PD: Mean pepinemab serum concentrations for all patients dosed with 10mg/kg are presented in comparison to mean cellular SEMA4D levels (2A), total soluble SEMA4D levels (2B), and cellular SEMA4D receptor occupancy / saturation (2C). Cmax (2D) and AUC0-t (2E) is shown for each dose group as well as trough pepinemab levels at each 2 week Cycle (2F). PK parameters in D-F are reported as mean +/- SEM.
Supplementary Methods from A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors
Authors: Chida Keigo , Kawazoe Akihito , Kawazu Masahito , Suzuki Toshihiro , Nakamura Yoshiaki , Nakatsura Tetsuya , Kuwata Takeshi , Ueno Toshihide , Kuboki Yasutoshi , Kotani Daisuke , Kojima Takashi , Taniguchi Hiroya , Mano Hiroyuki , Ikeda Masafumi , Shitara Kohei , Endo Itaru , Yoshino Takayuki
Published: April 2023

The details of Whole-exome sequencing and Multiplex fluorescence IHC
Supplementary Figure S2 from A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors
Authors: Chida Keigo , Kawazoe Akihito , Kawazu Masahito , Suzuki Toshihiro , Nakamura Yoshiaki , Nakatsura Tetsuya , Kuwata Takeshi , Ueno Toshihide , Kuboki Yasutoshi , Kotani Daisuke , Kojima Takashi , Taniguchi Hiroya , Mano Hiroyuki , Ikeda Masafumi , Shitara Kohei , Endo Itaru , Yoshino Takayuki
Published: April 2023

(A) Kaplan-Meier plots of progression-free survival according to PTEN mutations (B) Kaplan-Meier plots of overall survival according to PTEN mutations
Supplementary Table S1 from Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Authors: Laumont Céline M. , Wouters Maartje C.A. , Smazynski Julian , Gierc Nicole S. , Chavez Elizabeth A. , Chong Lauren C. , Thornton Shelby , Milne Katy , Webb John R. , Steidl Christian , Nelson Brad H.
Published: April 2023

Supplementary Table S1 presents relevant information pertaining to patients included in this study.
Supplementary Figure S7 from Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Authors: Laumont Céline M. , Wouters Maartje C.A. , Smazynski Julian , Gierc Nicole S. , Chavez Elizabeth A. , Chong Lauren C. , Thornton Shelby , Milne Katy , Webb John R. , Steidl Christian , Nelson Brad H.
Published: April 2023

Supplementary Figure S7 shows representative raw dot plots depicting PD1 expression on CD103+/- and CD39+/- subpopulations between CD8+ and CD4+ TILs.
Supplementary Figure S2 from Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Authors: Laumont Céline M. , Wouters Maartje C.A. , Smazynski Julian , Gierc Nicole S. , Chavez Elizabeth A. , Chong Lauren C. , Thornton Shelby , Milne Katy , Webb John R. , Steidl Christian , Nelson Brad H.
Published: April 2023

Supplementary Figure S2 shows the percentage of relevant cell subsets within total live cells from HGSC tumor samples, paired ascites samples or unmatched PBMC from healthy donors.
Supplementary Figure S12 from Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Authors: Laumont Céline M. , Wouters Maartje C.A. , Smazynski Julian , Gierc Nicole S. , Chavez Elizabeth A. , Chong Lauren C. , Thornton Shelby , Milne Katy , Webb John R. , Steidl Christian , Nelson Brad H.
Published: April 2023

Supplementary Figure S12 shows the expression level of genes associated with tissue-resident memory CD8+ T cells across triple-positive, 'other' and triple-negative CD8+ T cell subsets.
Supplemental Figure 1 from Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [64Cu]Cu-NOTA-anti-CD8 PET
Authors: Nagle Veronica L. , Henry Kelly E. , Hertz Charli Ann J. , Graham Maya S. , Campos Carl , Parada Luis F. , Pandit-Taskar Neeta , Schietinger Andrea , Mellinghoff Ingo K. , Lewis Jason S.
Published: April 2023

Purification and Stability of [64Cu]Cu-NOTA-anti-CD8. (a) Purification of [64Cu]Cu-NOTA-anti-CD8 quantified by iTLC. (b) Stability of [64Cu]Cu-NOTA-anti-CD8 in human serum at 37 ï,°C quantified by iTLC (n = 3/time point).
Supplementary Table 1 from Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer
Authors: Guardia Cristina , Bianchini Giampaolo , Arpí-LLucià Oriol , Menendez Silvia , Casadevall David , Galbardi Barbara , Dugo Matteo , Servitja Sonia , Montero Juan Carlos , Soria-Jiménez Luis , Sabbaghi MohammadA , Peña Raul , Madoz-Gúrpide Juan , Lloveras Belen , Lluch Ana , Eroles Pilar , Arribas Joaquin , Pandiella Atanasio , Gianni Luca , Rojo Federico , Rovira Ana , Albanell Joan
Published: April 2023

Supplementary Table 1 shows main clinical-pathological characteristics of HER2-positive breast cancer patients whom primary CAF cultures were derived from.
Figure S3 from Non-invasive Detection of Immunotherapy-Induced Adverse Events
Authors: Ferreira Carolina A. , Heidari Pedram , Ataeinia Bahar , Sinevici Nicoleta , Sise Meghan E. , Colvin Robert B. , Wehrenberg-Klee Eric , Mahmood Umar
Published: April 2023

Supplementary Figure S3
Supplementary Materials and Methods from The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions
Authors: Odintsov Igor , Lui Allan J.W. , Sisso Whitney J. , Gladstone Eric , Liu Zebing , Delasos Lukas , Kurth Renate I. , Sisso Exequiel M. , Vojnic Morana , Khodos Inna , Mattar Marissa S. , de Stanchina Elisa , Leland Shawn M. , Ladanyi Marc , Somwar Romel
Published: April 2023

Supplementary Materials and Methods contains additional details of experimental procedures.
Supplementary Figure S5 from The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions
Authors: Odintsov Igor , Lui Allan J.W. , Sisso Whitney J. , Gladstone Eric , Liu Zebing , Delasos Lukas , Kurth Renate I. , Sisso Exequiel M. , Vojnic Morana , Khodos Inna , Mattar Marissa S. , de Stanchina Elisa , Leland Shawn M. , Ladanyi Marc , Somwar Romel
Published: April 2023

Supplementary Figure S5 shows additional analysis of the seribantumab efficacy in the LUAD-0061AS3 PDX model
Supplementary Figure S4 from The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions
Authors: Odintsov Igor , Lui Allan J.W. , Sisso Whitney J. , Gladstone Eric , Liu Zebing , Delasos Lukas , Kurth Renate I. , Sisso Exequiel M. , Vojnic Morana , Khodos Inna , Mattar Marissa S. , de Stanchina Elisa , Leland Shawn M. , Ladanyi Marc , Somwar Romel
Published: April 2023

Supplementary Figure S4 shows the effect of seribantumab treatment on protein phosphorylation in HCC-95 cells.
Supplementary Figure S2 from The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions
Authors: Odintsov Igor , Lui Allan J.W. , Sisso Whitney J. , Gladstone Eric , Liu Zebing , Delasos Lukas , Kurth Renate I. , Sisso Exequiel M. , Vojnic Morana , Khodos Inna , Mattar Marissa S. , de Stanchina Elisa , Leland Shawn M. , Ladanyi Marc , Somwar Romel
Published: April 2023

Supplementary Figure S2 shows that cell lines without NRG1 fusions are insensitive to seribantumab and the IC50 for inhibition of growth of cells by seribantumab.
Supplementary Data from Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer
Authors: Marshall Catherine H. , Fu Wei , Wang Hao , Park Jong Chul , DeWeese Theodore L. , Tran Phuoc T. , Song Daniel Y. , King Serina , Afful Michaella , Hurrelbrink Julia , Manogue Charlotte , Cotogno Patrick , Moldawer Nancy P. , Barata Pedro C. , Drake Charles G. , Posadas Edwin M. , Armstrong Andrew J. , Sartor Oliver , Antonarakis Emmanuel S.
Published: April 2023

Figure legends and Supplementary Table
Figure S4 from Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer
Authors: Marshall Catherine H. , Fu Wei , Wang Hao , Park Jong Chul , DeWeese Theodore L. , Tran Phuoc T. , Song Daniel Y. , King Serina , Afful Michaella , Hurrelbrink Julia , Manogue Charlotte , Cotogno Patrick , Moldawer Nancy P. , Barata Pedro C. , Drake Charles G. , Posadas Edwin M. , Armstrong Andrew J. , Sartor Oliver , Antonarakis Emmanuel S.
Published: April 2023

Figure S4
Supplementary Methods from PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates
Authors: Veach Darren R. , Storey Claire M. , Lückerath Katharina , Braun Katharina , von Bodman Christian , Lamminmäki Urpo , Kalidindi Teja , Strand Sven-Erik , Strand Joanna , Altai Mohamed , Damoiseaux Robert , Zanzonico Pat , Benabdallah Nadia , Pankov Dmitry , Scher Howard I. , Scardino Peter , Larson Steven M. , Lilja Hans , McDevitt Michael R. , Thorek Daniel L.J. , Ulmert David
Published: April 2023

Supplementary Methods
Figure S1 from Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer
Authors: Marshall Catherine H. , Fu Wei , Wang Hao , Park Jong Chul , DeWeese Theodore L. , Tran Phuoc T. , Song Daniel Y. , King Serina , Afful Michaella , Hurrelbrink Julia , Manogue Charlotte , Cotogno Patrick , Moldawer Nancy P. , Barata Pedro C. , Drake Charles G. , Posadas Edwin M. , Armstrong Andrew J. , Sartor Oliver , Antonarakis Emmanuel S.
Published: April 2023

Figure S1
Supplementary Figure S2 from PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates
Authors: Veach Darren R. , Storey Claire M. , Lückerath Katharina , Braun Katharina , von Bodman Christian , Lamminmäki Urpo , Kalidindi Teja , Strand Sven-Erik , Strand Joanna , Altai Mohamed , Damoiseaux Robert , Zanzonico Pat , Benabdallah Nadia , Pankov Dmitry , Scher Howard I. , Scardino Peter , Larson Steven M. , Lilja Hans , McDevitt Michael R. , Thorek Daniel L.J. , Ulmert David
Published: April 2023

Supplementary Figure S2. Autoradiography of whole mounted KLK3_Hi-MYC GEMM prostate sections obtained 120h p.i. of [89Zr]hu5A10 (A) or [90Y]hu5A10 (B). Radioimmunoconjugate activity was detected in regions expressing PSA, but not in adjacent tissues lacking PSA expression, such as seminal vesicles and urethra.
Table S2 from An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer
Authors: Bai Yalai , Cole Kimberly , Martinez-Morilla Sandra , Ahmed Fahad Shabbir , Zugazagoitia Jon , Staaf Johan , Bosch Ana , Ehinger Anna , Nimeus Emma , Hartman Johan , Acs Balazs , Rimm David L.
Published: April 2023

Areas of assessment
Figure S6 from An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer
Authors: Bai Yalai , Cole Kimberly , Martinez-Morilla Sandra , Ahmed Fahad Shabbir , Zugazagoitia Jon , Staaf Johan , Bosch Ana , Ehinger Anna , Nimeus Emma , Hartman Johan , Acs Balazs , Rimm David L.
Published: April 2023

Correlation of QuPath machine read TIL scores of TMA cores to tissues in WTS format
Supplementary Table S5, from A Novel Topical Fluorescent Probe for Detection of Glioblastoma
Authors: Kitagawa Yosuke , Tanaka Shota , Kamiya Mako , Kuriki Yugo , Yamamoto Kyoko , Shimizu Takenori , Nejo Takahide , Hana Taijun , Matsuura Reiko , Koike Tsukasa , Yamazawa Erika , Kushihara Yoshihiro , Takahashi Satoshi , Nomura Masashi , Takami Hirokazu , Takayanagi Shunsaku , Mukasa Akitake , Urano Yasuteru , Saito Nobuhito
Published: April 2023

Real-time PCR original data of lysates from surgical specimens
Supplementary Data from Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Authors: Smith Catherine C. , Viny Aaron D. , Massi Evan , Kandoth Cyriac , Socci Nicholas D. , Rapaport Franck , Najm Matthieu , Medina-Martinez Juan S. , Papaemmanuil Elli , Tarver Theodore C. , Hsu Henry H. , Le Mai H. , West Brian , Bollag Gideon , Taylor Barry S. , Levine Ross L. , Shah Neil P.
Published: April 2023

Table S1
Supplementary Data from Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Authors: Smith Catherine C. , Viny Aaron D. , Massi Evan , Kandoth Cyriac , Socci Nicholas D. , Rapaport Franck , Najm Matthieu , Medina-Martinez Juan S. , Papaemmanuil Elli , Tarver Theodore C. , Hsu Henry H. , Le Mai H. , West Brian , Bollag Gideon , Taylor Barry S. , Levine Ross L. , Shah Neil P.
Published: April 2023

Table S4
Table S1 from MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer
Authors: Neven Patrick , Johnston Stephen R.D. , Toi Masakazu , Sohn Joohyuk , Inoue Kenichi , Pivot Xavier , Burdaeva Olga , Okera Meena , Masuda Norikazu , Kaufman Peter A. , Koh Han , Grischke Eva-Maria , Conte PierFranco , Lu Yi , Haddad Nadine , Hurt Karla C. , Llombart-Cussac Antonio , Sledge George W.
Published: April 2023

Treatment Discontinuation, Drug Exposure, and Dose Adjustment